Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice

Golkar, Majid; Shokrgozar, Mohammad Ali; Rafati, Sima; Musset, Karine; Assmar, Mehdi; Sadaie, R.; Cesbron-Delauw, Marie-France; Mercier, Corinne

doi:10.1016/j.vaccine.2007.02.057

Cited by 73 publications

(70 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Administration of the full length recombinant Toxoplasma GRA2 or GRA6 protein antigen in combination with MPL adjuvant led to a Th1 response in mice [303]. Similar Th1 effects were also observed with vaccine Fluzone [304] or recombinant antigens [305], both adjuvanted with synthesized hesaacylated lipid A derivatives in mice and Leishmania sterol 24-c-methyltransferase antigen with MPL-SE [306].…”

Section: Monophosphoryl Lpid A/lipidssupporting

confidence: 53%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

Section: Monophosphoryl Lpid A/lipidssupporting

confidence: 53%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

“…The construction of the pUET-GRA2 plasmid expressing amino acids 21 to 185 of GRA2 (protein with a deletion of its signal peptide) of type II T. gondii (the ME49 strain) and the purification of the corresponding recombinant protein from Escherichia coli were performed by the Proteogenix company (Oberhausbergen, France), similarly to what was described previously by Golkar et al (15). One microliter of either a solution (15.6 g/ml) of recombinant pUET-GRA2 fusion protein (rGRA2) or pUET peptide was deposited onto 5-mm-diameter discs of a nitrocellulose membrane.…”

Section: -Dementioning

confidence: 99%

Toxoplasma gondii Antigens Recognized by IgG Antibodies Differ between Mice with and without Active Proliferation of Tachyzoites in the Brain during the Chronic Stage of Infection

Hester

Mullins

et al. 2012

Infect Immun

Self Cite

View full text Add to dashboard Cite

We examined whether tachyzoite proliferation in the brains of immunocompetent hosts during the chronic stage of infection with Toxoplasma gondii induces production of IgG antibodies that recognize parasite antigens different from those recognized by the antibodies of infected hosts that do not have tachyzoite growth. For this purpose, two groups of CBA/J mice, which display continuous tachyzoite growth in their brains during the later stage of infection, were infected, and one group received treatment with sulfadiazine to prevent tachyzoite proliferation during the chronic stage of infection. T. gondii antigens recognized by the IgG antibodies from these two groups of mice were compared using immunoblotting following separation of tachyzoite antigens by two-dimensional gel electrophoresis. Several antigens, including the microneme protein MIC2, the cyst matrix protein MAG1, and the dense granule proteins GRA4 and GRA7, were commonly recognized by IgG antibodies from both groups of mice. There were multiple antigens recognized mostly by IgG antibodies of only one group of mice, either with or without cerebral tachyzoite growth. The antigens recognized only by or mostly by the antibodies of mice with cerebral tachyzoite growth include MIC6, the rhoptry protein ROP1, GRA2, one heat shock protein HSP90, one (putative) HSP70, and the myosin heavy chain. These results indicate that levels of IgG antibody to only selected T. gondii antigens increase in association with cerebral tachyzoite proliferation (reactivation of infection) in immunocompetent hosts with chronic infection.

show abstract

“…On the other hand, a study using recombinant GRA2 and GRA6, adjuvanted with monophosphoryl A (MPL) found a significant reduction in the number of brain cysts in GRA2, but not GRA6, immunized CBA/J mice challenged with the T. gondii Prugniaud isolate. Combination of both antigens did not lead to enhanced protection (Golkar et al 2007).…”

Section: Inactivated Parasites Crude or Purified Antigens And Recombmentioning

confidence: 81%

“…Each of these has been used in experimental vaccines for toxoplasmosis over the years with varying degrees of success (Khan et al 1991, Debard et al 1996, Petersen et al 1998, Desholme et al 2000, Martin et al 2004, Cong et al 2005, Garcia et al 2005, Mévé-lec et al 2005, Golkar et al 2007, Zhang et al 2007a, b, Cui et al 2008, Jongert et al 2008b, Xue et al 2008a. A common theme emerges that adjuvants do increase the immune response to the antigen administered and usually, but not always, induce a degree of protection to a subsequent challenge.…”

Section: Adjuvantsmentioning

confidence: 99%